Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 125-132

  Hasegawa, Hideki ^a   Ichinohe, Takeshi ^a   Ainai, Akira ^a   Tamura, Shin Ichi ^a   Kurata, Takeshi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Adjuvant; Influenza virus; Mucosal immunity; Secretory IgA antibody

Indexed keywords

AMPLIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANTIBODY PRODUCTION; CROSS REACTION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC; REVIEW; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 77949429974     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3297     Document Type: Review

References (52)

1. Uiprasertkul M, Puthavathana P, Sangsiriwut K, et al. Influenza A H5N1 replication sites in humans. Emerg Infect Dis. 2005;11(7): 1036-1041.
2. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352(4):333-340.
3. Renger KB, Small PA Jr. Passive immunization: systemic and mucosal. In: Ogra LL, Lamm ME, McGhee JR, Mestecky J, Strober W, Bienenstock J, editors. Handbook of Mucosal Immunology. San Diego, CA: Academic Press; 1994:347-356.
4. Chen Z, Sahashi Y, Matsuo K, et al. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine. 1998;16(16):1544-1549.
5. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529-1531.
6. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101- 105.
7. Ichinohe T, Watanabe I, Ito S, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 2005;79(5):2910-2919.
8. Asahi-Ozaki Y, Itamura S, Ichinohe T, et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 2006;8(12-13):2706-2714.
9. Sloat BR, Cui Z. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine. 2006;24(40-41):6405-6413.
10. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol. 1983;37:529-549.
11. Hoskins TW, Davies JR, Smith AJ, Allchin A, Miller CL, Pollock TM. Influenza at Christ's Hospital: March, 1974. Lancet. 1976;1(7951):105- 108.
12. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet. 1979;1(8106):33-35.
13. Asanuma H, Thompson AH, Iwasaki T, et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods. 1997;202(2):123-131.
14. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol. 1989;146:13-25.
15. Brandtzaeg P, Baekkevold ES, Farstad IN, et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today. 1999;20(3):141-151.
16. Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today. 1992;13(6):219-224.
17. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75-88.
18. Tamura SI, Asanuma H, Ito Y, et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol. 1992;22(2):477-481.
19. Tamura S, Ito Y, Asanuma H, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol. 1992;149(3):981-988.
20. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004;350(9):896-903.
21. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo. 1994;8(4):599-604.
22. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S96-104.
23. Thompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI: polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis. 1996;15(7):580-587.
24. Adams M, Navabi H, Jasani B, et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine. 2003;21(7-8):787-790.
25. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998;279(5349):393-396.
26. Horimoto T, Fukuda N, Iwatsuki-Horimoto K, et al. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci. 2004;66(3):303-305.
27. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. Eur J Immunol. 1984;14(4):350-356.
28. Asahi Y, Yoshikawa T, Watanabe I, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol. 2002;168(6):2930-2938.
29. Hasegawa H, Ichinohe T, Strong P, et al. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol. 2005;75(1):130-136.
30. Ichinohe T, Watanabe I, Tao E, et al. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant. J Med Virol. 2006;78(7):954-963.
31. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001;357(9272):1937-1943.
32. Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet. 2006;367(9509):475-481.
33. Takada A, Kuboki N, Okazaki K, et al. Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. J Virol. 1999;73(10):8303-8307.
34. Tumpey TM, Renshaw M, Clements JD, Katz JM. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol. 2001;75(11):5141-5150.
35. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine. 2004;22(20):2566-2577.
36. Greenbaum E, Furst A, Kiderman A, et al. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J Med Virol. 2001;65(1):178-184.
37. Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, Fukumi H. Developments in mucosal influenza virus vaccines. Vaccine. 1994;12(14): 1303-1310.
38. Muszkat M, Greenbaum E, Ben-Yehuda A, et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine. 2003;21(11-12):1180-1186.
39. Muszkat M, Yehuda AB, Schein MH, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol. 2000;61(1):100-106.
40. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A. 2004;101(15):5598-5603.
41. Jacobs BL, Langland JO. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology. 1996;219(2):339-349.
42. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738.
43. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001;14(4):461-470.
44. Ichinohe T, Kawaguchi A, Tamura S, et al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect. 2007;9(11):1333-1340.
45. Ichinohe T, Tamura S, Kawaguchi A, et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007;196(9):1313-1320.
46. Ghendon Y. Cold-adapted, live influenza vaccines developed in Russia. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of Influenza. Boston, MA: Blackwell Science; 1998:391-399.
47. Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson KG, Webster RG, Hay AJ, editor. Textbook of Influenza. Boston, MA: Blackwell Science; 1998:373-390.
48. Maassab HF. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature. 1967;213(76):612-614.
49. Murphy BR. Mucosal immunity to viruses. In: Ogra LL, Lamm ME, McGhee JR, Mestecky J, Strober W, Bienenstock J, editors. Handbook of Mucosal Immunology. San Diego, CA: Academic Press; 1994.
50. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol. 1989;146:107-116.
51. Suguitan AL, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006;3(9):e360.
52. Yoshino N, Lu FX, Fujihashi K, et al. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. J Immunol. 2004;173(11):6850-6857.